Efficacy And Tolerability Of EPs 7630 In Patients (aged 6-18 Years Old) With Acute Bronchitis

Effect Increase
Trial Design Double blind
Trial Length 1-7 Days
Number of Subjects 400
Gender Both Genders
Age Range 7-12, 13-17
Body Types Average
Notes for this study:
Supplementation of 10-30mg of EPs7630 thrice daily in youth and adolescents with acute bronchitis over a week was able to reduce symptoms as assessed by the BSS in a dose-dependent manner (although all doses were more effective than placebo).

Full details on all 4 studies are available to Examine Plus members.